duvelisib

{
  "id": "MLC-T-ONC-002624",
  "term": "duvelisib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that came back or did not get better after treatment with at least two other therapies. It is also being studied in the treatment of other types of cancer. Duvelisib blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor. Also called Copiktra.",
    "An orally bioavailable, highly selective and potent small molecule inhibitor of the delta and gamma isoforms of phosphoinositide-3 kinase (PI3K) with potential immunomodulating and antineoplastic activities. Upon administration, duvelisib prevents the activation of the PI3K delta/gamma-mediated signaling pathways which may lead to a reduction in cellular proliferation in PI3K delta/gamma-expressing tumor cells. Unlike other isoforms of PI3K, the delta and gamma isoforms are overexpressed primarily in hematologic malignancies and inflammatory and autoimmune diseases. By selectively targeting these PI3K isoforms, PI3K signaling in normal, non-neoplastic cells is minimally or not affected which would result in a more favorable side effect profile."
  ],
  "synonyms": [
    "Copiktra"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/duvelisib/"
}